Otsuka Holdings: New FDA‑Backed Kidney Drug Could Ignite a Multi‑Year Rally
FDA-backed kidney breakthrough and ADHD catalyst support Otsuka’s breakout despite looming patent cliffs.
Elevator Pitch
- Accelerated FDA approvals and priority reviews bodes well for revenue growth ahead
- Upgraded sales expectations for key drug bets can counter patent expirations
- Otsuka Holdings' valuations look acceptable
- A confirmed breakout signals clear skies ahead
